Friday, March 29, 2024
News

Roche's Evrysdi (risdiplam) - the first and only oral treatment for adults and children two months or older suffering from Spinal Muscular Atrophy (SMA) - now available in India

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Business | July 29, 2021 6:45:32 PM IST
Mumbai (Maharashtra) [India], July 29 (ANI/PR Newswire): Roche today announced the launch of Evrysdi (risdiplam), the first and only approved treatment in India for Spinal Muscular Atrophy (SMA) patients.

Evrysdi was first approved by the US FDA in August 2020 and is today available in India within 11 months of the US approval. Since its launch, over 4,000 SMA patients across 50+ countries have benefitted from Evrysdi.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
Availability and cost of capital most im...
Religare Enterprises Ltd. (REL), Sir Gan...
BD India Launches UltraTouch; a New Age ...
The Art of Living upgrades its Bengaluru...
Introduction of T+0 rolling settlement c...
EC-Council Renews USD 3.5 Million Cybers...
More...
 
INDIA WORLD ASIA
'I want to work for tribals...': Sudam M...
Delhi HC dismisses Congress party plea c...
AAP Goa chief Amit Palekar arrives at ED...
Chirag Paswan confident of NDA winning a...
Delhi HC issues notice to ED on bail ple...
AAP's Saurabh Bharadwaj claims: 'Operati...
More...    
 
 Top Stories
Interest rate on small saving schem... 
Indian Open: Three Indians in top-1... 
Neurologist raises alarm on Epileps... 
"I never think that I will...": Kri... 
UAE: 'Birds of Goodness' executes 1... 
"Ready to contest from Mandi, if pa... 
"NDA will win 40 out of 40 seats in... 
Former IPS officer Sanjiv Bhatt con...